Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Widens Expanded Access, Will Accelerated Approval Gray Area Narrow?

Executive Summary

FDA's development of two rules to broaden the use of expanded access programs suggests the agency is continuing to position such programs as alternatives to accelerated approval

You may also be interested in...



FDA’s New Leadership May Be More Amenable To Expanded Access Programs

Patient activists say shift in Iplex case shows that the agency may begin to allow more compassionate use for products in development.

Clinical Trials Can Charge For Using Competitor Drugs Under FDA Proposed Rule

Clinical trial sponsors are permitted to charge for approved drugs obtained from competitors while conducting a clinical study evaluating an investigational drug under an FDA proposed rule

Clinical Trials Can Charge For Using Competitor Drugs Under FDA Proposed Rule

Clinical trial sponsors are permitted to charge for approved drugs obtained from competitors while conducting a clinical study evaluating an investigational drug under an FDA proposed rule

Related Content

UsernamePublicRestriction

Register

PS047036

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel